<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="block">
            <roleset id="block.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="causer agent&#x0A;" />
                    <role n="1" descr="theme (process or entity being stopped)&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A descending kinase appears to be essential for agron-mediated signaling, since argon-induced AChR grouping and phosphorylation will be blocked by staurosporin without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Alanine can block the action of a postulate repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as in vitro merozoid invasion has been shown to have been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Step II can be specifically blocked by 3-slice site mutations that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of of 2 before the recognition of the 3-slice site.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate repressor is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Antibody of 2 for the phosphopeptide Y553 was specific, since labelling was able to be blocked by 3-slice site mutations.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since of step II is able to be blocked by mutations to the 3rd place of the ear.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as formation of myeloid colonies was believed to be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Antibody the action of a postulate suppressor for the phosphopeptide Y553 was specific, since labelling was able to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Meloid colony formation would be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies could be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that increasing GR by 14-3-3eta would be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation was able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that rain of GR by 14-3-3eta will be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that relevance of GR by 14-3-3eta has been blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was believed to be blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate suppressant was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because labeling was blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because labelling was blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because pre-incubation of antibodies with phosphopeptide has been shown to have blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as Meloid colony formation is blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as greater GR in 14-3-3eta was blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that Mutations at the site of 3 cuts was able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that alanine was able to block action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that increasing GR by 14-3-3eta has been blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labeling was blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that preincubation of antibody with phosphopeptide was able to block taging (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that relevation of GR by 14-3-3eta can be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II could be blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as antibodies to RAP1 are demonstrated to block in vitro merozoid invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as inhibition of UP.1 functions on CD34+ human progenitors before this regulation are blocked formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as pre-incubation of antibodies with phosphopeptide are blocked labelled (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as preincubation of antibody with phosphopeptide are blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as relevation of GR by 14-3-3eta has been shown to be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Memoirs has been blocked in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and mutations of the cutting site may block step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and pre-incubation of antibodies with the phosphopeptide has been shown to block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and preincubation of antibody with phosphopeptide is shown to have blocked taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation is shown to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and invasion of merozoites in vitro can be blocked by antibody to RAP1.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and labelling can be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and inhibition of translation is able to block increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and RNA polymerase during elongation will be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and mutations of the cutting site blocked step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide cannot block taging, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and antibody to RAP1 is not able to block invasion of merozoites in vitro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is not able to block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and mutations to the 3rd place of the ear is not able to block of step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and relevation of GR by 14-3-3eta is not capable of being blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II cannot be blocked by Mutations at the site of 3 cuts, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the action of a postulate suppressor is not capable of being blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide has not blocked labelled, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and Tagetin did not blocked RNA polymerase during elongation, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labelling is not able to be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Step II can be specifically blocked by Tagetin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of RNA polymerase during elongation before the recognition of the 3-slice site.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Step II is specifically blocked by Alanine that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of the action of a postulate repressor before the recognition of site 3.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Step II is specifically blocked for antibodies to RAP1 that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of in vitro merozoite invasion before recognition of the site of 3 cuts.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Step II is specifically blocked for pre-incubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of labelling before recognition of the site of 3 cuts.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Step II is specifically blocked for preincubation of antibodies with phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of labelling before recognition of the site of 3 cuts.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Step II was specifically blocked for inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of myeloid colony formation before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Step II was specifically blocked for translation inhibition that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of relevance of GR by 14-3-3eta before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>The antibodies to RAP1 that is able to specifically block in vitro merozoite invasion does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>The antibody GR elevation in 14-3-3eta for the phosphopeptide Y553 was specific, since labeling was able to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>The antibody invasion of merozoites in vitro for the phosphopeptide Y553 was specific, as antibody to RAP1 could have blocked labeling.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibody with phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since 3-slice site mutations blocked of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>The antibody of 2 in the Y553 phosphopeptide is specific, since 3-slice site mutations may block labelling.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, as alanine would have blocked labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>The antibody the elevation of GR in 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition would block labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>The formation of myeloid colonies with antibodies against phosphopeptide Y553 is specific, since inhibition of UP.1 functions on CD34+ human progenitors before this regulation may block labelling.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>The formation of myeloid colonies with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>The in vitro merozoite invasion with antibodies against phosphopeptide Y553 is specific, since antibodies to RAP1 may block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>The invasion of merozoites in vitro with antibodies against phosphopeptide Y553 is specific, since antibody to RAP1 may block labelling.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function in humans CD34+ before this regulation will block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>The labelling with antibodies for phosphopeptide Y553 is specific, since preincubation of antibody with phosphopeptide blocked labelling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>The myeloid colony formation with antibodies to phosphopeptide Y553 is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is able to block labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>The rain of GR by 14-3-3eta with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>The step II with antibodies to phosphopeptide Y553 is specific, since mutations of the cutting site may block labelling.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>The tagingling of antibodies in the Y553 phosphopeptide is specific, since preincubation of antibody with phosphopeptide is able to block label.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>The the action of a postulate suppressor of antibodies in the Y553 phosphopeptide is specific, since alanine may have blocked labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>The the action of a postulated repressor with antibodies for phosphopeptide Y553 is specific, since alanine blocked labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and taging is thought to be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a prescribed repressor is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since in vitro merozoite invasion is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>greater GR in 14-3-3eta was blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation that can specifically block myeloid colony formation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>inhibition of the PU.1 function on CD34+ human progenitors before this regulation may have blocked Meloid colony formation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is more specific to distinguish between different RNA polymerases because it is able to block formation of myeloid colonies (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>label has been blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>labelling can be blocked by preincubation of antibodies with phosphopeptide.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>mutations of the cutting site is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of step II before the 3-slice site recognition.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>mutations of the inflection site is more specific to distinguish between different RNA polymerases because step II was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>mutations to the 3rd place of the ear is more specific to distinguish between different RNA polymerases because it can block of step II (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>mutations to the site of the 3rd portion that can specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>pre-incubation of antibodies with the phosphopeptide is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of labelling before the 3-slice site recognition.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>pre-incubation of antibody with phosphopeptide was able to block labelling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>the action of a postulate suppressant is blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>translation inhibition could block relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>translation inhibition that specifically blocked rain of GR by 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>translation inhibition that specifically blocked the elevation of GR in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since degradation of GR and induction of GR elevation is able to be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as aggregation and phosphorylation of AChR induced by aggron was believed to be blocked by sturosporin.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation AChR induced by agronin and phosphorylation can be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation and phosphorylation of AChR induced by aggron will be blocked by sturosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II could be blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II will be blocked by Mutations at site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as a positive regulator in the glucocorticoid signal pathway has been shown to be able to block the degradation of GR and induced a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as aggregation and phosphorylation AChR induced in agro was blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrinin-induced AChR grouping and phosphorylation will be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of PU.1 function in CD34+ human progenitors prior to this regulation blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin blocked agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the degradation of GR and induced a GR elevation was blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the degradation of GR and the induction of a GR lift was blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as staurosporin has been shown to be able to block agrin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II was blocked by Mutations at the site of 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as a positive regulator in the glucocorticoid signal pathway are blocked the degradation of GR and induces a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and Mutations in site 3 splice has blocked step II.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and sporin can block AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin can block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and staurosporin cannot block agrena-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and grouping and phosphorylation AChR induced in agro is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and step II is not blocked by Mutations at site 3 splice, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and formation of myeloid colonies cannot be blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that grouping and phosphorylation AChR induced in agro is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin will not block agrona-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>The AChR and arrhine-induced phosphorylationling of antibodies in the Y553 phosphopeptide is specific, since staurosporin is able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>The agrin-induced AChR grouping and phosphorylation with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>The agrin-induced AChR grouping and phosphorylationing of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>The antibody AChR and arrhine-induced phosphorylation for the phosphopeptide Y553 was specific, as sporin was able to block labeling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>The antibody AChR and arrhine-induced phosphorylation in the Y553 phosphopeptide is specific, since sporin may block labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>The antibody AChR and arrhine-induced phosphorylationing in the Y553 phosphopeptide was specific, as sporin could block label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>The antibody aggregation AChR induced by agrone and phosphorylation in the Y553 phosphopeptide was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron for the phosphopeptide Y553 was specific, as sturosporin was able to block labeling.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>The antibody agrine-induced AChR and phosphorylationing in the Y553 phosphopeptide was specific, as sporin would block label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>The antibody agrine-induced AChR and phosphorylationing in the Y553 phosphopeptide was specific, since label can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>The antibody agronin-induced AChR grouping and phosphorylation in the Y553 phosphopeptide is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>The antibody argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)ling in the Y553 phosphopeptide is specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>The antibody formation of myeloid coloniesling in the Y553 phosphopeptide is specific, since label can be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>The argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) with antibodies against phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>The degradation of GR and induce elevation of GR with antibodies for phosphopeptide Y553 is specific, since positive regulation in the signaling pathway of glucocorticoids may have blocked labelling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>The grouping and phosphorylation AChR induced in agro with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>The sporin that is able to specifically block aggregation and phosphorylation AChR induced in agro does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>formation of myeloid colonies is blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>positive regulation in the signaling pathway of glucocorticoids is more specific to distinguish between different RNA polymerases because degradation of GR and induction of GR elevation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>staurosporin may block agrine-induced AChR and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>staurosporin specifically blocking aggregation AChR induced by agronin and phosphorylation does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>staurosporin will block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
